LP

Louise P. Short

Chief Financial Officer

Cingulate Therapeutics

Cingulate Therapeutics Pipeline

DrugIndicationPhase
CTx-1301Attention-Deficit/Hyperactivity Disorder (ADHD)Phase 3
CTx-1302Attention-Deficit/Hyperactivity Disorder (ADHD)Phase 3
CTx-2103Generalized Anxiety Disorder (GAD)Phase 2